Industries > Pharma > Next-Generation Biologics Market 2018-2028

Next-Generation Biologics Market 2018-2028

Revenue Forecasts and R&D Trends for Therapeutic Antibody Technologies, Insulins, Growth Hormones, Recombinant Coagulation Factors and Regenerative Medicine

PUBLISHED: 12 March 2018
PAGES: 262
PRODUCT CODE: PHA0294

Clear
WOOCS 2.2.1
DOWNLOAD SAMPLE

Next Generation Biologics Market Report 2018-2028: Forecasts by Market and Segments
• Do you need definitive Next Generation Biologics market data?
• Do you want to understand clear demarcation between next generation biologics and traditional biologics?
• Next Generation Biologics and sub-segment market analysis?
• Key drivers and constrains accompanied by this market?
• Clear leaders and lagers?
• Next wave of blockbusters and drivers impacting them?

Read on to discover how this definitive report can transform your own research and save you time.
The introduction of new pipeline drugs in Next generation biologics, has led visiongain to publish this timey report. The Next generation biologics market is expected to flourish in the next few years because of emergence of new phase III as well as marketed candidates which are going change the course of the market. Not only new candidates, but the technology (drug delivery as well as the mechanism of action) are novel which make the report a worth find and insightful.

Next-Generation Biologics Market 2018-2028

Report highlights

• 140 quantitative tables, charts, and graphs

• Analysis of key players in Next generation biologics Market
• Abbvie
• Roche/ Genentech
• Amgen
• GSK
• Eli Lilly
• Sanofi Aventis
• Novo Nordisk
• Seattle Genetics

• Global next generation biologics market outlook and analysis from 2018-2028

• Regional Next generation biologics market forecasts from 2018-2028
• US forecast 2018-2028,
• Japan forecast 2018-2028
• India forecast 2018-2028
• Germany forecast 2018-2028
• UK forecast 2018-2028
• France forecast 2018-2028
• Italy forecast 2018-2028
• Spain forecast 2018-2028
• China forecast 2018-2028

• Key questions answered
• What does the future hold for the next generation biologics?
• Where should you target your business strategy?
• Which applications should you focus upon?
• Which disruptive technologies should you invest in?
• Which companies should you form strategic alliances with?
• Which company is likely to success and why?
• What business models should you adopt?
• What industry trends should you be aware of?

• Target audience
• Leading Pharmaceutical companies
• Suppliers
• Contractors
• Technologists
• R&D staff
• Consultants
• Analysts
• CEO’s
• CIO’s
• COO’s
• Business development managers
• Investors
• Governments
• Agencies
• Industry organisations
• Banks

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Next-Generation Biologics Market 2018-2028


Download sample pages

Complete the form below to download your free sample pages for Next-Generation Biologics Market 2018-2028


Latest Pharma news

“Global Influenza Vaccines Market Set to Grow to $4.9bn by 2024” says new Visiongain report

The global vaccines market is one that is driven by innovation. This is vital for maintaining the rich pipeline of vaccines seen in the human vaccines market.

05 July 2019

READ

“Pharmaceutical Wholesale & Distribution Organizations 2019 is estimated to reach $1.4bn in 2024” says Visiongain report

Opportunities in the market stem from the increasing use of specialist and generic drugs, which have higher profit margins; global expansion into the emerging markets; vertical integration of wholesalers; and the increasing use of pharmaceuticals.

28 June 2019

READ

“Global Vaccines Sales market set to grow to $75bn by 2024” says new Visiongain report

Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs. This will also lead to more innovative approaches to vaccine development.

25 June 2019

READ

“Global Inflammatory Bowel Diseases (IBD) Drug Market is estimated to reach $8.6bn by 2024” says new Visiongain report

Revenue growth will be driven by rising incidence and prevalence owing to modern lifestyles and improved awareness and diagnosis.

21 June 2019

READ

Categories

Category